Evidence map›Paper›PMID 36539890›Full record

ArticleBreast cancer research : BCR2022

Definition of a novel breast tumor-specific classifier based on secretome analysis.

Philémon Sirven, Lilith Faucheux, Maximilien Grandclaudon, Paula Michea, Anne Vincent-Salomon, Fatima Mechta-Grigoriou, Alix Scholer-Dahirel, Maude Guillot-Delost, Vassili Soumelis

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Philémon Sirven *INSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France.
Lilith Faucheux *INSERM U976, Université de Paris, IRSLHôpital Saint Louis, 75006, Paris, France.
Maximilien GrandclaudonINSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France.
Paula MicheaINSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France.
Anne Vincent-SalomonParis Sciences Lettres (PSL) University, Paris, France.
Fatima Mechta-GrigoriouParis Sciences Lettres (PSL) University, Paris, France.
Alix Scholer-DahirelINSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France.
Maude Guillot-Delost *INSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France. maude.delost@curie.fr.
Vassili Soumelis *INSERM Unit U932, Immunity and Cancer, Institut Curie, Paris, France. vassili.soumelis@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring cancer development, the normal tissue microenvironment is shaped by tumorigenic events. Inflammatory mediators and immune cells play a key role during this process. However, which molecular features most specifically characterize the malignant tissue remains poorly explored.

methodsWithin our institutional tumor microenvironment global analysis (T-MEGA) program, we set a prospective cohort of 422 untreated breast cancer patients. We established a dedicated pipeline to generate supernatants from tumor and juxta-tumor tissue explants and quantify 55 soluble molecules using Luminex or MSD. Those analytes belonged to five molecular families: chemokines, cytokines, growth factors, metalloproteinases, and adipokines.

resultsWhen looking at tissue specificity, our dataset revealed some breast tumor-specific characteristics, as IL-16, as well as some juxta-tumor-specific secreted molecules, as IL-33. Unsupervised clustering analysis identified groups of molecules that were specific to the breast tumor tissue and displayed a similar secretion behavior. We identified a tumor-specific cluster composed of nine molecules that were secreted fourteen times more in the tumor supernatants than the corresponding juxta-tumor supernatants. This cluster contained, among others, CCL17, CCL22, and CXCL9 and TGF-β1, 2, and 3. The systematic comparison of tumor and juxta-tumor secretome data allowed us to mathematically formalize a novel breast cancer signature composed of 14 molecules that segregated tumors from juxta-tumors, with a sensitivity of 96.8% and a specificity of 96%.

conclusionsOur study provides the first breast tumor-specific classifier computed on breast tissue-derived secretome data. Moreover, our T-MEGA cohort dataset is a freely accessible resource to the biomedical community to help advancing scientific knowledge on breast cancer.

Indexed as

Breast NeoplasmsMammary Neoplasms, AnimalAnimalsBreastCytokinesFemaleHumansProspective StudiesSecretomeTumor MicroenvironmentCytokinesBreast cancerBreast tumor-specific signatureJuxta-tumorSecretomeTumor

Identifiers

PMID36539890
PMCPMC9764559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.